Atomoxetine Indication
Atomoxetine is FDA-approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in both children (age 6 and older), adolescents, and adults. 1
Primary Indication
Atomoxetine is a selective norepinephrine reuptake inhibitor specifically indicated for ADHD treatment across the lifespan 1. It represents the first nonstimulant medication approved by the FDA for ADHD and notably, the only agent approved for ADHD treatment in adults at the time of its initial approval 2, 3.
Clinical Context for Use
Position in Treatment Algorithm
According to major clinical practice guidelines, atomoxetine serves as:
- A nonstimulant alternative when stimulants are contraindicated, not tolerated, or ineffective 4
- First-line option in patients with substance abuse risk, as it carries negligible abuse potential and is not a controlled substance 5, 3
- Preferred choice in patients with comorbid anxiety disorders or tic disorders 5, 6
Multiple Asian guidelines (Singapore, Malaysia, India, Japan, South Korea) list atomoxetine as an approved ADHD medication, though methylphenidate is typically recommended as first-line 7.
Specific Patient Populations
Atomoxetine is particularly indicated for:
- Patients who do not respond adequately to or cannot tolerate stimulant medications 8
- Patients with ADHD and comorbid substance use disorders (alcohol, cannabis, nicotine) 9, 6
- Patients with ADHD and comorbid anxiety or depression, where atomoxetine does not exacerbate these conditions 6
- Patients or families who prefer not to use a controlled substance 3
Age-Specific Considerations
For preschool children (under age 6): Atomoxetine is NOT recommended as first-line. Methylphenidate is the preferred medication in this age group due to lack of sufficient rigorous study data for nonstimulants in preschoolers 4.
For school-age children and adolescents (age 6-18): Atomoxetine is fully approved and effective, though stimulants remain first-line in most guidelines 4, 8.
For adults: Atomoxetine represents a validated treatment option with specific FDA approval based on adult clinical trials 3.
Adjunctive Use
Atomoxetine may be used in combination with stimulant medications on an off-label basis when stimulant monotherapy provides insufficient symptom control, though this has limited supporting evidence compared to guanfacine or clonidine for adjunctive therapy 4.
Critical Safety Considerations
Black Box Warning
Atomoxetine carries an FDA black box warning for increased risk of suicidal ideation in children and adolescents 1. Patients started on therapy require close monitoring for suicidality, clinical worsening, or unusual behavioral changes, though no actual suicides occurred in clinical trials 4, 1.
Contraindications
Atomoxetine is contraindicated in:
- Patients with narrow-angle glaucoma 1
- Pheochromocytoma or history thereof 1
- Severe cardiovascular disorders that may deteriorate with increases in heart rate and blood pressure 1
- Within 2 weeks of MAOI use 1
Pre-Treatment Screening
Before initiating atomoxetine, obtain: